Exploring how proteomics and SILAC technology reveal new biomarkers and treatment targets for castration-resistant prostate cancer.
Discover how ibrutinib, a blood cancer drug, is being repurposed to make prostate cancer responsive to immunotherapy by targeting tumor-infiltrating B cells.